TABLE 4

Potential Impact of 68Ga-PSMA-11 PET/CT on RT Planning Based on CTVs Treating Prostate and Seminal Vesicles With or Without Pelvic LNs

ParameternOut-of-field PSMA-positive findingsPSMA pattern
RT to prostate and seminal vesicles with pelvic LNs73
 Major impact on RT planning outside CTV12 (16.5%)
 Extension of prostate CTV1 (1.5%)1 T outN0M0
 Extension of consensus pelvic LN CTV2 (2.5%)2 N outN1M0
 Extension of both prostate CTV and consensus pelvic LN CTV2 (2.5%)2 T out + N outN1M0
 Oligometastasis-directed SBRT (≤5 M1a or M1b)3 (4%)2 M1bN0M1b
 1 M1a + M1bN1M1aM1b
 Oligometastasis-directed SBRT + extension of prostate CTV1 (1.5%)1 T out + M1bN1M1a
 RT futile because of polymetastatic or visceral disease3 (4%)1 M1aN1M1a
 1 N out + M1aN1M1a
 1 M1b + M1cN1M1bM1c
RT to prostate and seminal vesicles without pelvic LNs66
 Major impact on RT planning outside CTV21 (32%)
 Addition of whole pelvic LN CTV13 (19.5%)13 N outN1M0
 Extension of prostate CTV1 (1.5%)1 T outN0M0
 Extension of both prostate and consensus pelvic LN CTV1 (1.5%)1 T out + N outN1M0
 Oligometastasis-directed SBRT (≤5 M1a or M1b)3 (4.5%)2 M1bN0M1b
 1 M1a + M1bN1M1aM1b
 Oligometastasis-directed SBRT + extension of prostate CTV1 (1.5%)1 T out + M1aN1M1a
 RT futile because of polymetastatic or visceral disease3 (4.5%)1 M1aN1M1a
 1 N out + M1aN1M1a
 1 M1b + M1cN1M1bM1c

  • SBRT = stereotactic body RT.